Gilead Sciences Inc

Latest stories

16h
Business Wire
Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc.NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an inves
Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc.
Business Wire / Posted 16 hours ago
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Gilead Sciences Inc. (“Gilead Sciences” or the “Company”) (NASDAQ:GILD) concerning possible violations of federal securities laws. On May 6, 2016, Gilead... Read more
1d
FOX Business
Gilead Sciences Inc. vs. Johnson & JohnsonImage source: Johnson & Johnson. They're two of the biggies in healthcare. Gil
Gilead Sciences Inc. vs. Johnson & Johnson
FOX Business / Posted yesterday
Image source: Johnson & Johnson. They're two of the biggies in healthcare. Gilead Sciences Inc. grew to become the largest biotech in the world over the last decade on the back of its HIV and hepatitis C franchises. Meanwhile, Johnson & Johnson has... Read more
10 related stories
1d
FOX Business
Gilead Sciences Inc. vs. Johnson & JohnsonImage source: Johnson & Johnson. Continue Reading Below They're two of the bi
Gilead Sciences Inc. vs. Johnson & Johnson
FOX Business / Posted yesterday
Image source: Johnson & Johnson. Continue Reading Below They're two of the biggies in healthcare. Gilead Sciences Inc. grew to become the largest biotech in the world over the last decade on the back of its HIV and hepatitis C franchises.... Read more
10 related stories
2d
FOX Business
Billionaires Are Bailing on Gilead Sciences -- Should You, Too?Image source: Gilead Sciences, Inc. While following blindly in the footsteps o
Billionaires Are Bailing on Gilead Sciences -- Should You, Too?
FOX Business / Posted 2 days ago
Image source: Gilead Sciences, Inc. While following blindly in the footsteps of billionaires is risky, it's always interesting to see what stocks legendary investing gurus are selling, especially when it involves a widely held stock like Gilead... Read more
10 related stories
2d
FOX Business
Billionaires Are Bailing on Gilead Sciences -- Should You, Too?Image source: Gilead Sciences, Inc. Continue Reading Below While following bl
Billionaires Are Bailing on Gilead Sciences -- Should You, Too?
FOX Business / Posted 2 days ago
Image source: Gilead Sciences, Inc. Continue Reading Below While following blindly in the footsteps of billionaires is risky, it's always interesting to see what stocks legendary investing gurus are selling, especially when it involves a widely... Read more
10 related stories
3d
FOX Business
Gilead Sciences Names Kevin Young COOGilead Sciences Inc. said late Tuesday that it was appointing Kevin Young as ch
Gilead Sciences Names Kevin Young COO
FOX Business / Posted 3 days ago
Gilead Sciences Inc. said late Tuesday that it was appointing Kevin Young as chief operating officer. Young served for 10 years as Gilead's vice president of commerical operations and most recently has been a senior advisor to the biotech company.... Read more
3d
FOX Business
Gilead Sciences Names Kevin Young COOGilead Sciences Inc. said late Tuesday that it was appointing Kevin Young as ch
Gilead Sciences Names Kevin Young COO
FOX Business / Posted 3 days ago
Gilead Sciences Inc. said late Tuesday that it was appointing Kevin Young as chief operating officer. Young served for 10 years as Gilead's vice president of commerical operations and most recently has been a senior advisor to the biotech company.... Read more
4d
FOX Business
Your 2016 Guide to Investing in Gilead Sciences StockImage source: Gilead Sciences via Google Maps. Gilead Sciences is one of the l
Your 2016 Guide to Investing in Gilead Sciences Stock
FOX Business / Posted 4 days ago
Image source: Gilead Sciences via Google Maps. Gilead Sciences is one of the largest biotechnology companies, so you might be interested in how it makes money. If you're considering an investment in Gilead Sciences, you might also want to know how... Read more
10 related stories
4d
FOX Business
Your 2016 Guide to Investing in Gilead Sciences StockImage source: Gilead Sciences via Google Maps. Continue Reading Below Gilead
Your 2016 Guide to Investing in Gilead Sciences Stock
FOX Business / Posted 4 days ago
Image source: Gilead Sciences via Google Maps. Continue Reading Below Gilead Sciences is one of the largest biotechnology companies, so you might be interested in how it makes money. If you're considering an investment in Gilead Sciences, you might... Read more
10 related stories
7d
Business Wire
Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) toda
Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23
Business Wire / Posted 7 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the UBS Global Healthcare Conference in New York. Norbert W. Bischofberger, Gilead’s Executive Vice... Read more
13d
Marshalltown Times-Republican
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
Marshalltown Times-Republican / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
TribLIVE
Vermont poised to require drug companies to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont poised to require drug companies to explain price increases
TribLIVE / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
CTV News
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
CTV News / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
Daily Herald
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
Daily Herald / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
The Mercury News
Vermont to become first state to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to become first state to require drug makers to explain price increases
The Mercury News / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
Boston Globe
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
Boston Globe / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings’ modest income, big... Read more
13 related stories
13d
WTSP-TV Tampa
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
WTSP-TV Tampa / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
The Wilmington Star-News
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
The Wilmington Star-News / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
Spartanburg Herald-Journal
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
Spartanburg Herald-Journal / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
Island Packet
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
Island Packet / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
The Hendersonville Times-News
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
The Hendersonville Times-News / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
13d
The Lexington Dispatch
Vermont to require drug makers to explain price increaseson Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recent
Vermont to require drug makers to explain price increases
The Lexington Dispatch / Posted 13 days ago
on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C. Both drugs are expensive, though for people of the Messings' modest income, big... Read more
13 related stories
16d
The Economic Times
Patent not to affect hepatitis C drug price in India: Gilead Sciences IncNEW DELHI: US-based pharmaceuticals firm Gilead Sciences Inc today said prices
Patent not to affect hepatitis C drug price in India: Gilead Sciences Inc
The Economic Times / Posted 16 days ago
NEW DELHI: US-based pharmaceuticals firm Gilead Sciences Inc today said prices of its hepatitis C drug Sovaldi will not be impacted by granting of patent to it by the country's patent office. Although the medicine is quoted at $1,000 a pill in the... Read more
3 related stories
22d
Boston Globe
Joe Kennedy III owns stock in expensive Hep C drugUS Representative Joseph Kennedy III has earned stock value of up to $434,999 f
Joe Kennedy III owns stock in expensive Hep C drug
Boston Globe / Posted 22 days ago
US Representative Joseph Kennedy III has earned stock value of up to $434,999 from investments in Gilead Sciences, Inc., the manufacturer of a controversially priced hepatitis C drug, Sovaldi, that many of Kennedy’s constituents are struggling to... Read more
23d
Market Watch
Merck revenue hit by generic competition, dollarfor hepatitis C, the latest entrant in a booming market for drugs for the viral
Merck revenue hit by generic competition, dollar
Market Watch / Posted 23 days ago
for hepatitis C, the latest entrant in a booming market for drugs for the viral infection -- a market now dominated by Gilead Sciences Inc. Merck had initial sales of $50 million for Zepatier in the first quarter. The company posted a profit... Read more
7 related stories
23d
Daily Mail
Hepatitis C now kills more Americans than 60 other infectious diseasescancer, liver disease, inflammation of the liver, and other hep C-related disea
Hepatitis C now kills more Americans than 60 other infectious diseases
Daily Mail / Posted 23 days ago
cancer, liver disease, inflammation of the liver, and other hep C-related diseases. Darryl Kato, research scientist for Gilead Sciences Inc., works on the synthesis of a potential hepatitis C virus drug candidate at the company's lab in Foster... Read more
29 related stories
25d
FOX Business
Good News: Gilead Sciences Discounted Its Drugs AgainImage source: Gilead Sciences, inc. Gilead Sciences reported its Q1 2016 earn
Good News: Gilead Sciences Discounted Its Drugs Again
FOX Business / Posted 25 days ago
Image source: Gilead Sciences, inc. Gilead Sciences reported its Q1 2016 earnings on April 29, and on the surface things looked pretty ugly for the hepatitis C treatment leader. Gilead missed analyst estimates on both revenue and earnings, and HCV... Read more
7 related stories
25d
FOX Business
Good News: Gilead Sciences Discounted Its Drugs AgainImage source: Gilead Sciences, inc. Continue Reading Below Gilead Sciences r
Good News: Gilead Sciences Discounted Its Drugs Again
FOX Business / Posted 25 days ago
Image source: Gilead Sciences, inc. Continue Reading Below Gilead Sciences reported its Q1 2016 earnings on April 29, and on the surface things looked pretty ugly for the hepatitis C treatment leader. Gilead missed analyst estimates on both... Read more
7 related stories
25d
TheStreet.com
Don't give up on gilead following a weak q1at least, according to Porges. Gilead and Merck reportedly have until today to
Don't give up on gilead following a weak q1
TheStreet.com / Posted 25 days ago
at least, according to Porges. Gilead and Merck reportedly have until today to file additional arguments. The case is Gilead Sciences Inc. v. Merck & Co., 13-cv-04057, U.S. District Court, Northern District of California (San Jose). Beyond... Read more
25d
Investopedia
Gilead Stock Punished on Q1 Earnings Miss (GILD)Is it time to exit Gilead Sciences Inc. (GILD) or has a buying opportunity been
Gilead Stock Punished on Q1 Earnings Miss (GILD)
Investopedia / Posted 25 days ago
Is it time to exit Gilead Sciences Inc. (GILD) or has a buying opportunity been created? That's the question investors must reconcile after watching shares of the biopharmaceutical company plunge almost 10% on Friday on heavy trading volume following... Read more
7 related stories
26d
Investopedia
The 3 Largest Alpha-Seeking ETFs (PKW, PDP)in the portfolio is Apple Inc. (NASDAQ: AAPL) at 2.99%, followed by The Priceli
The 3 Largest Alpha-Seeking ETFs (PKW, PDP)
Investopedia / Posted 26 days ago
in the portfolio is Apple Inc. (NASDAQ: AAPL) at 2.99%, followed by The Priceline Group Inc. (NASDAQ: PCLN) with 2.83% and Gilead Sciences Inc. (NASDAQ: GILD) at 2.67%. With AUM of $1.43 billion and average daily volume of $15.79 million, as of... Read more
8 related stories
28d
The Auto Channel
Young Scientists from Around the State Will Compete For Top Honors at the 65th California State Science FairSouthern California Gas Company, THE MUSES of the California Science Center Fou
Young Scientists from Around the State Will Compete For Top Honors at the 65th California State Science Fair
The Auto Channel / Posted 28 days ago
Southern California Gas Company, THE MUSES of the California Science Center Foundation, The Ralph M. Parsons Foundation and Gilead Sciences, Inc. Robert Curbeam, vice president of Mission Assurance,� Quality and Raytheon Six Sigma™ for Raytheon... Read more
28d
Daily Herald
Molina Healthcare and Seagate skid, Amazon surgesdeals site's first-quarter results met expectations, but investors remained con
Molina Healthcare and Seagate skid, Amazon surges
Daily Herald / Posted 28 days ago
deals site's first-quarter results met expectations, but investors remained concerned about the health of its business. Gilead Sciences Inc., down $8.79 to $88.21 The biotech drugmaker's results were hurt by big discounts and rebates on its... Read more
28d
Investopedia
Gilead Stock: Analyzing 5 Key Suppliers (GILD)Gilead Sciences Inc. (NASDAQ: GILD) is a medical research and biopharmaceutical
Gilead Stock: Analyzing 5 Key Suppliers (GILD)
Investopedia / Posted 28 days ago
Gilead Sciences Inc. (NASDAQ: GILD) is a medical research and biopharmaceutical firm based in California. It develops and markets medicines targeting a wide variety of life-threatening illnesses, including cardiovascular disease, HIV/AIDS,... Read more
28d
FOX Business
Stocks Struggle To Hold Monthly Gains As Earnings, Data Weighdespite those gainers, the overall mood remained sour, hurt by weak reports fro
Stocks Struggle To Hold Monthly Gains As Earnings, Data Weigh
FOX Business / Posted 28 days ago
despite those gainers, the overall mood remained sour, hurt by weak reports from Twitter Inc.(TWTR) and Gilead Sciences Inc.(GILD) released earlier in the week. Baidu.com Inc. (BIDU) shares soared after profit fell, but revenue... Read more
3 related stories
28d
FOX Business
Stocks Struggle To Hold Monthly Gains As Earnings, Data Weighdespite those gainers, the overall mood remained sour, hurt by weak reports fro
Stocks Struggle To Hold Monthly Gains As Earnings, Data Weigh
FOX Business / Posted 28 days ago
despite those gainers, the overall mood remained sour, hurt by weak reports from Twitter Inc.(TWTR) and Gilead Sciences Inc.(GILD) released earlier in the week. Baidu.com Inc. (BIDU) shares soared after profit fell, but revenue... Read more
3 related stories
29d
FOX Business
9 Figures That Sum Up Gilead Sciences' First QuarterImage source: Gilead Sciences, Inc. After reporting first-quarter financials t
9 Figures That Sum Up Gilead Sciences' First Quarter
FOX Business / Posted 29 days ago
Image source: Gilead Sciences, Inc. After reporting first-quarter financials that were shy of industry watchers' forecast, Gilead Sciencesshares were trading down 5% after the bell today. Investors wondering if Gilead Sciences shares are a buy or... Read more
13 related stories
29d
FOX Business
9 Figures That Sum Up Gilead Sciences' First QuarterImage source: Gilead Sciences, Inc. Continue Reading Below After reporting fi
9 Figures That Sum Up Gilead Sciences' First Quarter
FOX Business / Posted 29 days ago
Image source: Gilead Sciences, Inc. Continue Reading Below After reporting first-quarter financials that were shy of industry watchers' forecast, Gilead Sciencesshares were trading down 5% after the bell today. Investors wondering if Gilead... Read more
13 related stories
29d
The Tampa Tribune
Gilead 1Q profit tumbles on slower hepatitis C drug salesforecast of Wall Street analysts who were looking for earnings of $3.12 per sha
Gilead 1Q profit tumbles on slower hepatitis C drug sales
The Tampa Tribune / Posted 29 days ago
forecast of Wall Street analysts who were looking for earnings of $3.12 per share, according to Zacks Investment research. Gilead Sciences Inc., based in Foster City, California, has grown into one of the world's biggest drugmakers thanks to its... Read more
13 related stories
29d
Market Watch
Gilead reports drop in hepatitis C drug revenueGilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the f
Gilead reports drop in hepatitis C drug revenue
Market Watch / Posted 29 days ago
Gilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations, suggesting competition is eating into the company's hold on a hot corner of the drug... Read more
13 related stories
29d
FOX Business
Gilead Shares Fall After Company Misses On RevenueGilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biot
Gilead Shares Fall After Company Misses On Revenue
FOX Business / Posted 29 days ago
Gilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biotech company reported lower-than-expected first-quarter sales. Gilead said it earned an adjusted $4.3 billion, or $3.03 a share, in the quarter, compared with $4.6 billion,... Read more
13 related stories
29d
FOX Business
Gilead Shares Fall After Company Misses On RevenueGilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biot
Gilead Shares Fall After Company Misses On Revenue
FOX Business / Posted 29 days ago
Gilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biotech company reported lower-than-expected first-quarter sales. Gilead said it earned an adjusted $4.3 billion, or $3.03 a share, in the quarter, compared with $4.6 billion,... Read more
29d
Chattanooga Times Free Press
Gilead 1Q profit tumbles on slower hepatitis C drug salesforecast of Wall Street analysts who were looking for earnings of $3.12 per sha
Gilead 1Q profit tumbles on slower hepatitis C drug sales
Chattanooga Times Free Press / Posted 29 days ago
forecast of Wall Street analysts who were looking for earnings of $3.12 per share, according to Zacks Investment research. Gilead Sciences Inc., based in Foster City, California, has grown into one of the world's biggest drugmakers thanks to its... Read more
13 related stories
29d
Market Watch
Gilead reports drop in Hepatitis C drug revenueGilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the f
Gilead reports drop in Hepatitis C drug revenue
Market Watch / Posted 29 days ago
Gilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations. Shares in the company slid 5.3% in after-hours trading. The Foster City, Calif.,... Read more
13 related stories
29d
Daily Herald
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 billionthe statement: • Viekira Pak sales of $414 million, estimate was $514 million.
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 billion
Daily Herald / Posted 29 days ago
the statement: • Viekira Pak sales of $414 million, estimate was $514 million. The hepatitis C therapy is competing with Gilead Sciences Inc. and Merck & Co.'s treatments • Imbruvica sales of $381 million; average estimate was $367 million •... Read more
32 related stories
29d
Chicago Tribune
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 billionthe statement: --Viekira Pak sales of $414 million, estimate was $514 million.
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 billion
Chicago Tribune / Posted 29 days ago
the statement: --Viekira Pak sales of $414 million, estimate was $514 million. The hepatitis C therapy is competing with Gilead Sciences Inc. and Merck & Co.'s treatments --Imbruvica sales of $381 million; average estimate was $367... Read more
32 related stories
29d
Crain's Chicago Business
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 Billionthe statement: Viekira Pak sales of $414 million, estimate was $514 million. T
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 Billion
Crain's Chicago Business / Posted 29 days ago
the statement: Viekira Pak sales of $414 million, estimate was $514 million. The hepatitis C therapy is competing with Gilead Sciences Inc. and Merck & Co.’s treatments Imbruvica sales of $381 million; average estimate was $367 million Net... Read more
32 related stories

People in this news